Compare BGT & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGT | CGEN |
|---|---|---|
| Founded | N/A | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 317.3M | 270.4M |
| IPO Year | 2004 | 2001 |
| Metric | BGT | CGEN |
|---|---|---|
| Price | $10.97 | $2.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 101.7K | ★ 534.9K |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $75.09 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.22 | $1.29 |
| 52 Week High | $12.76 | $3.24 |
| Indicator | BGT | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 50.00 | 55.79 |
| Support Level | $10.83 | $1.46 |
| Resistance Level | $11.14 | $3.24 |
| Average True Range (ATR) | 0.08 | 0.17 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 40.32 | 38.13 |
Blackrock Floating Rate Income Trust is a diversified closed-end management investment company. Its investment objective is to provide a high level of current income. The company, as a secondary objective, also focuses on preservation of capital to the extent consistent with its primary objective of high current income. The Trust seeks to achieve its investment objectives by investing in worl-wide portfolio of floating rate securities, including investing a substantial amount in U.S. and non-U.S. senior secured floating rate loans (Senior Loans), made to corporate and other business entities.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.